Philips’ new IntelliSpace Portal 10 highlights integration with InVivo for expansion into breast and prostate cancer imaging informatics solutions.
Health technology provider Royal Philips has announced the launch of IntelliSpace Portal 10, the newly updated version of their advanced visualization and quantification platform. The update provides a focus on oncology and tools to provide radiologists with an improved set of applications and workflows for reading and follow-up of complex oncology cases.
The updated portal also includes a 3D modeling application and DynaCAD Prostate and Breast solutions through integration with InVivo.
See also: A smarter breast cancer diagnosis, thanks to deep learning
“IntelliSpace Portal 10 highlights our continued commitment to creating advanced visualization platforms that offer a single integrated solution for fast, efficient workflows and increased diagnostic confidence, especially in a value-based care environment,” said Yair Briman, Business Leader Healthcare Informatics at Philips.
“This new edition marks Philips’ ability to provide one comprehensive solution to answer our customers’ needs, such as clinical improvements and increased efficiencies, especially now with the integration of two important clinical domains of breast and prostate cancer,” Briman added.
Philips integrates machine learning
The portal uses machine learning that automatically learns from prior app usage to predict the series and data type on which pre-processing should be applied. It is designed to be a single platform that is not dependent on any particular vendor. The company said it hopes to strengthen diagnostic confidence to improve patient outcomes and reduce costs.
DynaCAD Prostate and Breast capabilities will be directly integrated into this latest edition of IntelliSpace Portal; these are high-performance advanced image analysis solutions that feature flexible workspaces with custom hanging protocols, image post-processing, lesion segmentation, standardized and structured reporting and interventional biopsy planning. They should help reduce processing time to assist with enhanced disease management, the company said in its announcement.
